Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 12/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 10/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 10/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 7/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | SLC2A1 | P11166 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.95 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.95 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.95 |
| ▸ | DRD1 | P21728 | 1/20 | 0.95 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.95 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.95 |
| ▸ | HTR1D | P28221 | 1/20 | 0.95 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.95 |
| ▸ | HTR7 | P34969 | 1/20 | 0.95 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.95 |
| ▸ | HRH1 | P35367 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7127774 | 0.89 | ADRA2A (1.00) | KDM1AADRA2AADRA2CADRA2BGLA | |
| SCHEMBL7124492 | 0.87 | KDM1A (0.79) | KDM1AADRA2AADRA2CADRA2BGLA | |
| SCHEMBL14389067 | 0.87 | KDM1A (0.84) | KDM1AADRA2AADRA2CADRA2BGLA | |
| SCHEMBL7124493 | 0.86 | KDM1A (0.77) | KDM1AADRA2AADRA2CADRA2BGLA | |
| SCHEMBL6821547 | 0.85 | ADRA2A (1.00) | KDM1AADRA2AADRA2CADRA2BGLA | |
| SCHEMBL7126115 | 0.85 | KDM1A (0.74) | KDM1AADRA2AADRA2CADRA2BGLA | |
| SCHEMBL7117912 | 0.85 | KDM1A (1.00) | KDM1AADRA2AADRA2CADRA2BGLA | |
| SCHEMBL7121656 | 0.84 | KDM1A (1.00) | KDM1AADRA2AADRA2CADRA2BGLA | |
| SCHEMBL7130095 | 0.84 | ADRA2A (1.00) | KDM1AADRA2AADRA2CADRA2BGLA | |
| SCHEMBL7126445 | 0.84 | KDM1A (0.72) | KDM1AADRA2AADRA2CADRA2BGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074899-A1 | A2-ADRENOCEPTOR SUBTYPE C ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2025-03-06 | — | — | US | disclosed |
| US-20250057828-A1 | COMBINATION OF AN A2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A NOREPINEPHRINE REUPTAKE INHIBITOR FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2025-02-20 | — | — | US | disclosed |
| US-20250049779-A1 | COMBINATION OF AN A2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A NOREPINEPHRINE REUPTAKE INHIBITOR FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2025-02-13 | — | — | US | disclosed |
| US-20250049788-A1 | 2,3-DIHYDROBENZO [B][1, 4]DIOXIN-2-YLMETHYL)PIPERAZIN-1-YL DERIVATES FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2025-02-13 | — | — | US | disclosed |
| CN-118785902-A | Alpha 2-adrenoceptor subtype C antagonists for the treatment of sleep apnea | 拜耳公司 | 2024-10-15 | — | — | CN | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| CN-113166166-B | Alpha 2-adrenoreceptor subtype C (alpha-2C) antagonists for the treatment of sleep apnea | 拜耳公司 | 2024-09-10 | — | — | CN | disclosed |
| CN-118510514-A | 2, 3-Dihydrobenzo [ b ] [1,4] dioxin-2-ylmethyl) piperazin-1-yl derivatives for the treatment of sleep apnea | 拜耳公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-118434414-A | Combinations of alpha 2-adrenoceptor subtype C (alpha-2C) antagonists and muscarinic receptor antagonists for the treatment of sleep apnea | 拜耳公司 | 2024-08-02 | — | — | CN | disclosed |
| US-20240000767-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2024-01-04 | — | — | US | disclosed |
| WO-2010042475-A1 | SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS | SCHERING CORPORATION (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010017120-A1 | CYCLOPROPYLCHROMENE DERIVATIVES AS MODULATORS OF THE ALPHA-2C RECEPTOR | SCHERING CORPORATION (US) | 2010-02-11 | — | — | WO | disclosed |
| US-20050203100-A1 | Use of an alfa2-adrenoreceptor antagonist for cns-related diseases | ORION CORPORATION (FI) | 2005-09-15 | — | — | US | disclosed |
| EP-1490338-A1 | USE OF AN ALFA2-ADRENORECEPTOR ANTAGONIST FOR CNS-RELATED DISEASES | ORION CORPORATION (FI) | 2004-12-29 | — | — | EP | disclosed |
| US-20030225078-A1 | Derivatives of quinoline as alpha-2 antagonists | ORION CORPORATION | 2003-12-04 | — | — | US | disclosed |
| WO-2003082825-A1 | USE OF AN ALFA2-ADRENORECEPTOR ANTAGONIST FOR CNS-RELATED DISEASES | ORION CORPORATION (FI) | 2003-10-09 | — | — | WO | disclosed |
| US-6593324-B2 | P-aminoanilino- derivatives | ORION CORPORATION (FI) | 2003-07-15 | — | — | US | disclosed |
| EP-1263733-A2 | DERIVATIVES OF QUINOLINE AS ALPHA-2 ANTAGONISTS | ORION CORPORATION FARMOS (FI) | 2002-12-11 | — | — | EP | disclosed |
| US-20010046991-A1 | Derivatives of quinoline as alpha-2 antagonists | OY JUVANTIA PHARMA LTD. (FI) | 2001-11-29 | — | — | US | disclosed |
| WO-2001064645-A2 | DERIVATIVES OF QUINOLINE AS ALPHA-2 ANTAGONISTS | ORION CORPORATION (FI) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074899-A1 | A2-ADRENOCEPTOR SUBTYPE C ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA | ADRA2C, ADRA2A, ADRB2 | KDM1A 470/4885ADRA2A 2/4885ADRA2C 1/4885 |
| US-20250057828-A1 | COMBINATION OF AN A2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A NOREPINEPHRINE REUPTAKE INHIBITOR FOR THE TREATMENT OF SLEEP APNEA | ADRA2C, ADRB2, ADRA2A | KDM1A 1844/4885ADRA2A 3/4885ADRA2C 1/4885 |
| US-20250049788-A1 | 2,3-DIHYDROBENZO [B][1, 4]DIOXIN-2-YLMETHYL)PIPERAZIN-1-YL DERIVATES FOR THE TREATMENT OF SLEEP APNEA | ADRA2C, ADRB2, ADRA2B | KDM1A 547/4885ADRA2A 4/4885ADRA2C 1/4885 |
| US-20240000767-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | ADRA2C, ADRB2, CHRNA2 | KDM1A 1052/4885ADRA2A 8/4885ADRA2C 1/4885 |
| US-20250049779-A1 | COMBINATION OF AN A2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A NOREPINEPHRINE REUPTAKE INHIBITOR FOR THE TREATMENT OF SLEEP APNEA | ADRA2C, ADRB2, ADRA2A | KDM1A 1976/4885ADRA2A 3/4885ADRA2C 1/4885 |
| US-20030225078-A1 | Derivatives of quinoline as alpha-2 antagonists | ADRB2, ADRA2A, ADRB1 | KDM1A 1512/4885ADRA2A 2/4885ADRA2C 6/4885 |
| US-20010046991-A1 | Derivatives of quinoline as alpha-2 antagonists | ADRB2, ADRA2A, ADRB1 | KDM1A 1512/4885ADRA2A 2/4885ADRA2C 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.